# Pyxis Oncology, Inc. (PYXS) — capital_raise/private_placement [announced]
Source: SEC API (secapi.ai) · situation sit_c124060e9faed0aee67a · retrieved 2026-08-16T21:05:05.649Z

## Overview
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers, with its lead candidate micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate targeting extradomain-B of fibronectin in the tumor microenvironment.

Pyxis Oncology, Inc. completed a private placement financing on July 2, 2026, receiving approximately $50 million in upfront gross proceeds (before placement agent fees and offering expenses) from new and existing healthcare-focused investors. The financing was announced in June 2026 with a total capacity of up to $114 million, including approximately $64 million in additional gross proceeds if accompanying warrants are exercised in full for cash. The upfront proceeds, combined with existing cash, extended the company's cash runway into the second quarter of 2027.

## Terms
- Deal value: $114.0M · Consideration: cash

## Key dates
- Announced 2026-08-13

## Timeline
- 2026-08-13 · 8-K (0001193125-26-347911): 8-K - Pyxis Oncology, Inc. — *Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers, with its lead candidate micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate targeting extradomain-B of fibronectin in the tumor microenvironment.* Pyxis Oncology, Inc. completed a private placement financing on July 2, 2026, receiving approximately $50 million in upfront gross proceeds (before placement agent fees and offering expenses) from new and existing healthcare-focused investors. The financing was announced in June 2026 with a total capacity of up to $114 million, including approximately $64 million in additional gross proceeds if accompanying warrants are exercised in full for cash. The upfront proceeds, combined with existing cash, extended the company's cash runway into the second quarter of 2027.
  https://www.sec.gov/Archives/edgar/data/1782223/0001193125-26-347911.txt

## Citations
- 0001193125-26-347911 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526347911